Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
about
Killing two birds with one stone: response to pembrolizumab in a patient with metastatic melanoma and B-cell chronic lymphocytic leukemia.Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation.The evolving role of targeted drugs in the treatment of Hodgkin lymphoma.Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma.The Challenge for Development of Valuable Immuno-oncology Biomarkers.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma.Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.Pembrolizumab in the treatment of advanced urothelial cancer.Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.Trial watch: Immune checkpoint blockers for cancer therapy.PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome.Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.Hodgkin lymphoma: A review and update on recent progress.Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors.Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences.Clinical Development of PD-1 Blockade in Hematologic Malignancies.Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma.Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.Immune evasion via PD-1/PD-L1 on NK-cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma.Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma.Blockade of Tumor-Expressed PD-1 promotes lung cancer growth.Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.Transplant strategies in relapsed/refractory Hodgkin lymphoma.Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma.Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.Response to the letter by Adams and Kwee, entitled: "Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma".Targeting Immune System Alterations in Hodgkin Lymphoma.PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy.Fertility preservation in Hodgkin's lymphoma patients that undergo targeted molecular therapies: an important step forward from the chemotherapy era.Cancer Immunotherapy and the Immune Response in Hodgkin Lymphoma.Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination.The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma.Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
P2860
Q38611996-167EBE4F-6C04-4BC7-B03A-C6AD026C5008Q38684561-DC6F39EF-41B2-42CC-B170-F3DA54101C03Q38700459-C423E4D6-956C-42F6-8217-E0BBD7E93B41Q42375641-0774A65E-0FD8-4C8D-9D8B-C0800948E483Q46008297-B1367D2E-D515-457C-B5DE-91E65CDAC9DBQ47120629-9A65999A-3DC2-4E80-BA1D-C4E2E9B08737Q47218634-177A1D3D-80CE-484A-A5AB-ABE266C586F0Q47329066-03208C30-CEDC-4823-84E6-2079BD4A1D5BQ47345366-80B3C039-282D-4BFD-8595-93A5020581E9Q47372804-DB4319EB-9198-4853-8680-2E178D046F00Q47393365-5903C4D8-A6E9-4B82-A61D-AA25866AA26AQ47424027-C3E00768-494D-46BC-8ECE-905CE1B98C16Q47563022-8245F901-F890-441E-9E5E-79FE2618AB62Q47602259-84CC577C-E81D-498A-AA56-A62708C359FCQ47718879-747B0F92-112D-41E4-8306-9609CE3D83DEQ47807176-78708E31-AB5C-435E-9597-84A401E9672CQ47821123-1D8FB49D-014B-4402-8CE5-DF1678CEF5D5Q47855599-5D21B955-3D51-4D21-AA38-D303408E9753Q47936113-1673CD9A-8690-462C-97D5-9C4925089439Q47952363-88254E3F-0AC9-4278-921B-AA405FDA2141Q48306002-5944D6B8-FE8C-4C9B-9498-43C7B1DDC7DBQ48526801-63475F7E-3BC5-4282-98B5-EBDBF6CF6799Q48689919-68821472-8989-4668-B786-B9808C826D4BQ49374190-0F2403B1-C70E-45BF-93A1-AB41F2958B71Q49961097-BD6FB14B-32F1-450D-8A00-0E9E4DD15AF6Q52560940-81949DAC-0A9E-4857-92E3-C96D42FFBFFBQ52569157-7D029546-EA5A-4083-98B3-73C6DA47F18CQ52597553-57422B25-94D7-4065-8C8D-42CB574AB723Q52647752-989AE137-B166-4A9C-A981-D3EAF6D2BE92Q52676516-D7D428F4-86E6-45FC-AB4F-910BCD98C437Q52680552-C1A05DB7-D55A-4BF2-88EF-BB89F63EF91AQ52721221-9656EC10-7C41-466B-87DA-BEE957FC254EQ52937933-F80AFBB7-B4EB-44A0-820B-A81C4801FEBEQ53123844-D8DEFAA9-6A3E-4C81-855D-A73B677F7E24Q55321107-EE854E1F-2B30-4E72-859E-B51222A97CC0Q55341751-61D309BE-5C12-4303-9C90-8869B7BA0C83Q55401659-D48C5AD6-7BA2-498A-A6F0-5B8E475D1A8EQ55491553-AF5FF2CF-A686-4A84-A65C-9BC485E6F4FCQ55495617-9BC8AC84-F807-4957-BE90-ACDB02A19700Q56383260-61E00D90-1878-4F85-A726-C91E749B8FF6
P2860
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Phase II Study of the Efficacy ...... tory Classic Hodgkin Lymphoma.
@ast
Phase II Study of the Efficacy ...... tory Classic Hodgkin Lymphoma.
@en
type
label
Phase II Study of the Efficacy ...... tory Classic Hodgkin Lymphoma.
@ast
Phase II Study of the Efficacy ...... tory Classic Hodgkin Lymphoma.
@en
prefLabel
Phase II Study of the Efficacy ...... tory Classic Hodgkin Lymphoma.
@ast
Phase II Study of the Efficacy ...... tory Classic Hodgkin Lymphoma.
@en
P2093
P2860
P356
P1476
Phase II Study of the Efficacy ...... tory Classic Hodgkin Lymphoma.
@en
P2093
Akihiro Tomita
Alejandro D Ricart
Arun Balakumaran
Bastian von Tresckow
Craig H Moskowitz
Daniel Molin
KEYNOTE-087
Margaret A Shipp
Michelle A Fanale
Nathalie A Johnson
P2860
P304
P356
10.1200/JCO.2016.72.1316
P407
P577
2017-04-25T00:00:00Z